Status:
COMPLETED
Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium
Lead Sponsor:
Seoul National University Hospital
Conditions:
Observation of Neuromuscular Block
Eligibility:
All Genders
19-69 years
Phase:
NA
Brief Summary
This study aims to find appropriate dose of neostigmine which is possible to reverse rocuronium or cisatracurium till train of four (TOF) 0.9 within 10 minutes.
Eligibility Criteria
Inclusion
- American Society of Anesthesiologist Physical status classification 1 or 2 elective surgery under general anesthesia
Exclusion
- BMI \>25 or \< 20 kg/m2
- Patients taking intercurrent medication
- Glutamic Oxalacetate Transaminase or Glutamic Pyruvate Transaminase \> 40 IU/L, Cr \> 1.4 mg/dl
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT01885715
Start Date
June 1 2013
End Date
June 1 2014
Last Update
June 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eunsu Choi
Seongnam-si, Gyeonggi-do, South Korea, 463-707